Skip to main content

LON:ABC - Abcam Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: GBX 1,402
  • Forecasted Upside: -5.91 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
GBX 1,490
▲ +18 (1.22%)
1 month | 3 months | 12 months
Get New Abcam Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ABC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ABC

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
GBX 1,402
▼ -5.91% Downside Potential
This price target is based on 6 analysts offering 12 month price targets for Abcam in the last 3 months. The average price target is GBX 1,402, with a high forecast of GBX 1,530 and a low forecast of GBX 1,300. The average price target represents a -5.91% upside from the last price of GBX 1,490.

Hold

The current consensus among 6 investment analysts is to hold stock in Abcam. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
11/14/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 1 sell ratings
2/12/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 1 sell ratings
5/12/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 1 sell ratings
8/10/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 1 sell ratings
11/8/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
2/6/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
4/7/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
5/7/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/10/2021Berenberg BankBoost Price TargetHoldGBX 1,180 ➝ GBX 1,300
i
3/9/2021JPMorgan Chase & Co.Lower Price TargetNeutralGBX 1,400 ➝ GBX 1,300
i
12/17/2020Peel HuntReiterated RatingHoldGBX 1,530
i
12/17/2020Peel HuntReiterated RatingHoldGBX 1,530
i
7/24/2020Royal Bank of CanadaLower Price TargetOutperformGBX 1,400 ➝ GBX 1,350
i
7/23/2020Liberum CapitalReiterated RatingHold
i
7/23/2020Peel HuntReiterated RatingAdd
i
7/10/2020JPMorgan Chase & Co.Boost Price TargetNeutralGBX 1,188 ➝ GBX 1,400
i
7/9/2020Royal Bank of CanadaBoost Price TargetOutperformGBX 1,300 ➝ GBX 1,400
i
7/2/2020Peel HuntReiterated RatingAdd
i
6/3/2020Peel HuntReiterated RatingAdd
i
5/1/2020Peel HuntReiterated RatingAdd
i
4/24/2020Peel HuntReiterated RatingAdd
i
4/20/2020Royal Bank of CanadaUpgradeOutperform
i
4/17/2020Peel HuntLower Price TargetAddGBX 1,250 ➝ GBX 1,220
i
4/17/2020Liberum CapitalLower Price TargetHoldGBX 1,290 ➝ GBX 1,260
i
4/7/2020Peel HuntReiterated RatingAdd
i
4/1/2020Peel HuntLower Price TargetAddGBX 1,470 ➝ GBX 1,250
i
3/20/2020Berenberg BankBoost Price TargetBuyGBX 1,330 ➝ GBX 1,450
i
3/18/2020Liberum CapitalBoost Price TargetHoldGBX 1,290 ➝ GBX 1,370
i
3/10/2020JPMorgan Chase & Co.Boost Price TargetNeutralGBX 1,134 ➝ GBX 1,188
i
3/9/2020Liberum CapitalReiterated RatingHoldGBX 1,370 ➝ GBX 1,290
i
3/4/2020Peel HuntReiterated RatingAdd
i
2/13/2020Peel HuntReiterated RatingAdd
i
2/5/2020Peel HuntReiterated RatingAdd
i
1/27/2020Peel HuntBoost Price TargetAddGBX 1,300 ➝ GBX 1,470
i
1/14/2020Peel HuntReiterated RatingAdd
i
1/10/2020Liberum CapitalReiterated RatingHoldGBX 1,230 ➝ GBX 1,370
i
1/6/2020Peel HuntReiterated RatingAdd
i
12/18/2019Panmure GordonDowngradeSell
i
12/18/2019Royal Bank of CanadaLower Price TargetSector PerformerGBX 1,300 ➝ GBX 1,250
i
12/5/2019Peel HuntReiterated RatingAdd
i
11/12/2019Royal Bank of CanadaReiterated RatingSector PerformerGBX 1,300
i
11/11/2019Liberum CapitalReiterated RatingHoldGBX 1,230
i
11/11/2019Peel HuntReiterated RatingAdd
i
11/4/2019Peel HuntReiterated RatingAdd
i
10/7/2019Peel HuntReiterated RatingAdd
i
9/30/2019Liberum CapitalInitiated CoverageHoldGBX 1,230
i
9/16/2019JPMorgan Chase & Co.Lower Price TargetNeutralGBX 1,144 ➝ GBX 1,134
i
9/9/2019Berenberg BankReiterated RatingBuyGBX 1,330
i
9/9/2019Peel HuntReiterated RatingAddGBX 1,430 ➝ GBX 1,300
i
9/2/2019Peel HuntReiterated RatingAdd
i
8/1/2019Peel HuntReiterated RatingAdd
i
7/22/2019Peel HuntLower Price TargetAddGBX 1,550 ➝ GBX 1,430
i
7/15/2019Peel HuntReiterated RatingAdd
i
7/3/2019Peel HuntReiterated RatingAdd
i
6/27/2019Peel HuntDowngradeAddGBX 1,330 ➝ GBX 1,550
i
6/4/2019Peel HuntReiterated RatingBuy
i
5/2/2019Peel HuntReiterated RatingBuy
i
4/2/2019Peel HuntReiterated RatingBuy
i
3/27/2019Peel HuntReiterated RatingBuy
i
3/25/2019Berenberg BankLower Price TargetBuyGBX 1,510 ➝ GBX 1,330
i
3/12/2019Peel HuntReiterated RatingBuy
i
3/4/2019Peel HuntReiterated RatingBuy
i
1/28/2019Peel HuntReiterated RatingBuy
i
1/10/2019JPMorgan Chase & Co.Reiterated RatingNeutral
i
1/9/2019Peel HuntUpgradeBuyGBX 1,350 ➝ GBX 1,330
i
1/8/2019Numis SecuritiesUpgradeAddGBX 1,340
i
1/8/2019Berenberg BankReiterated RatingBuyGBX 1,640
i
1/7/2019Peel HuntReiterated RatingHold
i
1/2/2019JPMorgan Chase & Co.Reiterated RatingNeutral
i
12/6/2018Peel HuntReiterated RatingHold
i
11/1/2018Peel HuntReiterated RatingHold
i
10/3/2018Peel HuntReiterated RatingHold
i
9/19/2018Peel HuntBoost Price TargetHoldGBX 1,100 ➝ GBX 1,350
i
9/11/2018Numis SecuritiesReiterated RatingHold
i
9/10/2018Peel HuntReiterated RatingHoldGBX 1,100
i
9/4/2018Peel HuntReiterated RatingHold
i
8/1/2018Peel HuntReiterated RatingHold
i
7/31/2018Berenberg BankUpgradeBuyGBX 1,230 ➝ GBX 1,640
i
7/12/2018Berenberg BankReiterated RatingHoldGBX 1,230
i
7/12/2018Numis SecuritiesReiterated RatingHoldGBX 1,380
i
7/12/2018Peel HuntReiterated RatingHoldGBX 1,100
i
7/3/2018Peel HuntReiterated RatingHold
i
5/31/2018Peel HuntReiterated RatingHold
i
5/10/2018Peel HuntReiterated RatingHold
i
5/3/2018Peel HuntReiterated RatingHoldGBX 1,100
i
4/4/2018Peel HuntReiterated RatingHold
i
3/15/2018JPMorgan Chase & Co.Boost Price TargetNeutralGBX 946 ➝ GBX 1,011
i
3/6/2018JPMorgan Chase & Co.Reiterated RatingNeutralGBX 946
i
3/5/2018Berenberg BankDowngradeHoldGBX 1,240 ➝ GBX 1,230
i
3/5/2018Peel HuntReiterated RatingHoldGBX 1,100
i
2/26/2018Peel HuntReiterated RatingHoldGBX 1,100
i
2/1/2018Peel HuntReiterated RatingHoldGBX 1,100
i
1/22/2018Peel HuntReiterated RatingHoldGBX 1,100
i
1/15/2018Peel HuntBoost Price TargetHoldGBX 1,020 ➝ GBX 1,100
i
1/8/2018JPMorgan Chase & Co.Reiterated RatingNeutralGBX 946
i
1/5/2018Berenberg BankReiterated RatingBuyGBX 1,240
i
1/5/2018Numis SecuritiesUpgradeBuyGBX 1,200
i
1/5/2018Peel HuntReiterated RatingHoldGBX 1,020
i
11/29/2017Peel HuntReiterated RatingHoldGBX 1,020
i
10/31/2017Peel HuntReiterated RatingHoldGBX 1,020
i
9/20/2017Peel HuntBoost Price TargetHoldGBX 750 ➝ GBX 1,020
i
9/18/2017JPMorgan Chase & Co.Boost Price TargetNeutralGBX 864 ➝ GBX 946
i
9/12/2017Numis SecuritiesBoost Price TargetAddGBX 1,116 ➝ GBX 1,200
i
9/12/2017JPMorgan Chase & Co.Reiterated RatingNeutralGBX 864
i
9/11/2017Berenberg BankReiterated RatingBuyGBX 1,100
i
9/11/2017Panmure GordonReiterated RatingSell
i
9/11/2017Peel HuntReiterated RatingHoldGBX 750
i
8/18/2017Peel HuntReiterated RatingHoldGBX 750
i
7/27/2017Panmure GordonReiterated RatingSell
i
7/27/2017Numis SecuritiesReiterated RatingAddGBX 1,116
i
6/27/2017Berenberg BankInitiated CoverageBuyGBX 1,100
i
5/2/2017Stifel NicolausReiterated RatingHoldGBX 890
i
4/20/2017Panmure GordonReiterated RatingSellGBX 680
i
4/4/2017Numis SecuritiesUpgradeAddGBX 912
i
4/4/2017Stifel NicolausReiterated RatingHoldGBX 890
i
3/27/2017JPMorgan Chase & Co.Boost Price TargetNeutralGBX 678 ➝ GBX 864
i
3/20/2017Panmure GordonReiterated RatingSellGBX 680
i
3/17/2017Numis SecuritiesReiterated RatingHoldGBX 912
i
3/17/2017Peel HuntReiterated RatingHoldGBX 750
i
3/7/2017Numis SecuritiesDowngradeHoldGBX 912
i
3/7/2017JPMorgan Chase & Co.Reiterated RatingNeutralGBX 678
i
3/6/2017Peel HuntReiterated RatingHoldGBX 750
i
2/24/2017Peel HuntReiterated RatingHoldGBX 750
i
1/26/2017Panmure GordonReiterated RatingSellGBX 680
i
1/25/2017Peel HuntInitiated CoverageHoldGBX 750
i
1/12/2017JPMorgan Chase & Co.Reiterated RatingNeutralGBX 678
i
1/10/2017Panmure GordonReiterated RatingSellGBX 640
i
1/10/2017Numis SecuritiesReiterated RatingAddGBX 870
i
1/4/2017JPMorgan Chase & Co.Reiterated RatingNeutralGBX 678
i
11/2/2016Panmure GordonReiterated RatingSellGBX 640
i
9/26/2016Panmure GordonBoost Price TargetSellGBX 636 ➝ GBX 640
i
9/13/2016JPMorgan Chase & Co.Boost Price TargetNeutralGBX 581 ➝ GBX 678
i
9/12/2016Numis SecuritiesReiterated RatingAddGBX 850
i
9/2/2016Numis SecuritiesReiterated RatingAddGBX 850
i
8/4/2016Panmure GordonInitiated CoverageSellGBX 636
i
8/3/2016Numis SecuritiesReiterated RatingAddGBX 850
i
7/26/2016JPMorgan Chase & Co.Reiterated RatingNeutralGBX 581
i
7/25/2016Numis SecuritiesReiterated RatingAddGBX 850
i
7/25/2016Stifel NicolausReiterated RatingHold
i
7/15/2016JPMorgan Chase & Co.Reiterated RatingNeutralGBX 581
i
6/24/2016Numis SecuritiesReiterated RatingAddGBX 700
i
(Data available from 5/8/2016 forward)
Abcam logo
Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Europe, the Middle East, Africa, and rest of Asia Pacific. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. Further, the company offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.
Read More

Today's Range

Now: GBX 1,490
1,464
1,496

50 Day Range

MA: GBX 1,456.54
1,391
1,528

52 Week Range

Now: GBX 1,490
1,142
1,740

Volume

230,581 shs

Average Volume

445,021 shs

Market Capitalization

£3.38 billion

P/E Ratio

N/A

Dividend Yield

0.91%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Abcam?

The following Wall Street research analysts have issued research reports on Abcam in the last year: Berenberg Bank, JPMorgan Chase & Co., Liberum Capital, Peel Hunt, Peel Hunt LLP, and Royal Bank of Canada.
View the latest analyst ratings for ABC.

What is the current price target for Abcam?

5 Wall Street analysts have set twelve-month price targets for Abcam in the last year. Their average twelve-month price target is GBX 1,402, suggesting a possible downside of 5.9%. Peel Hunt has the highest price target set, predicting ABC will reach GBX 1,530 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of GBX 1,300 for Abcam in the next year.
View the latest price targets for ABC.

What is the current consensus analyst rating for Abcam?

Abcam currently has 5 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ABC, but not buy more shares or sell existing shares.
View the latest ratings for ABC.

What other companies compete with Abcam?

How do I contact Abcam's investor relations team?

Abcam's physical mailing address is 330 Cambridge Science Park, CAMBRIDGE, CB4 0FL, United Kingdom. The company's listed phone number is +44-1223-696000. The official website for Abcam is www.abcam.com.